Eagle Pharmaceuticals, Inc.
Every calculator, already run for EGRX
Open the full toolkit →You have the numbers on EGRX. Get the argument.
A written report on which of these readings actually decide the outcome for Eagle Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for EGRX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3…
EGRX — frequently asked
Is EGRX a buy right now?
Wall Street's consensus rating on Eagle Pharmaceuticals, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is EGRX overvalued?
EGRX trades at 1.0x trailing earnings, against a DCF fair value of $113 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Eagle Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Eagle Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EGRX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Eagle Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.